SG10201913248VA - Agonistic antibodies that bind human cd40 and uses thereof - Google Patents

Agonistic antibodies that bind human cd40 and uses thereof

Info

Publication number
SG10201913248VA
SG10201913248VA SG10201913248VA SG10201913248VA SG10201913248VA SG 10201913248V A SG10201913248V A SG 10201913248VA SG 10201913248V A SG10201913248V A SG 10201913248VA SG 10201913248V A SG10201913248V A SG 10201913248VA SG 10201913248V A SG10201913248V A SG 10201913248VA
Authority
SG
Singapore
Prior art keywords
bind human
agonistic antibodies
agonistic
antibodies
bind
Prior art date
Application number
SG10201913248VA
Inventor
Tibor Keler
Joel Goldstein
Laura Vitale
Lizhen He
Tom O'neill
Andrea Crocker
Karuna Sundarapandiyan
Lawrence Thomas
Jenifer Widger
Original Assignee
Celldex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celldex Therapeutics Inc filed Critical Celldex Therapeutics Inc
Publication of SG10201913248VA publication Critical patent/SG10201913248VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG10201913248VA 2016-04-18 2017-04-18 Agonistic antibodies that bind human cd40 and uses thereof SG10201913248VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662324170P 2016-04-18 2016-04-18

Publications (1)

Publication Number Publication Date
SG10201913248VA true SG10201913248VA (en) 2020-02-27

Family

ID=58664791

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201913248VA SG10201913248VA (en) 2016-04-18 2017-04-18 Agonistic antibodies that bind human cd40 and uses thereof
SG11201808821WA SG11201808821WA (en) 2016-04-18 2017-04-18 Agonistic antibodies that bind human cd40 and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201808821WA SG11201808821WA (en) 2016-04-18 2017-04-18 Agonistic antibodies that bind human cd40 and uses thereof

Country Status (14)

Country Link
US (5) US20200377606A1 (en)
EP (1) EP3445783A2 (en)
JP (2) JP7038064B2 (en)
KR (1) KR102414558B1 (en)
CN (2) CN109071665B (en)
AU (1) AU2017252527A1 (en)
BR (1) BR112018071307A2 (en)
CA (1) CA3021328A1 (en)
EA (1) EA201892362A1 (en)
IL (1) IL262269B2 (en)
MA (1) MA44723A (en)
MX (1) MX2018012757A (en)
SG (2) SG10201913248VA (en)
WO (1) WO2017184619A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2796571C (en) 2010-04-13 2019-10-29 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
WO2017184619A2 (en) 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
KR20230149857A (en) 2016-07-07 2023-10-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Antibody adjuvant conjugates
CN110023337B (en) 2016-10-11 2024-01-05 艾吉纳斯公司 anti-LAG-3 antibodies and methods of use thereof
EP3684813A1 (en) * 2017-09-19 2020-07-29 MAB Discovery GmbH Agonistic cd40 antibodies
CN109971723B (en) * 2017-12-28 2023-07-07 上海细胞治疗研究院 T cells comprising CD40 antibody and muc1 specific chimeric antigen receptor gene and uses thereof
CN109971717B (en) * 2017-12-28 2023-06-20 上海细胞治疗研究院 T cells co-expressing CD40 antibody and mesothelin specific chimeric antigen receptor and uses thereof
US11459393B2 (en) 2018-04-17 2022-10-04 Celldex Therapeutics, Inc. Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
JP2021521804A (en) 2018-04-20 2021-08-30 リビジェン バイオファーマ カンパニー リミテッド Anti-CD40 antibody and its use
CN116178544A (en) 2018-09-28 2023-05-30 礼进生物医药科技（上海）有限公司 anti-CD 40 binding molecules with engineered Fc domains and therapeutic uses thereof
WO2020104690A1 (en) * 2018-11-23 2020-05-28 Quine Medical Ab Bi-specific conjugates
CN109734813B (en) 2019-01-28 2022-06-17 广东昭泰体内生物医药科技有限公司 Chimeric antigen receptor and application thereof
CN111454363B (en) * 2019-03-04 2021-03-02 北京天广实生物技术股份有限公司 CD40 antibodies and uses thereof
CA3130794A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
EP3947454A1 (en) * 2019-03-27 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Recombinant proteins with cd40 activating properties
US20220370418A1 (en) 2019-09-09 2022-11-24 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
CA3164129A1 (en) 2019-12-20 2021-06-24 Amgen Inc. Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors
AR121013A1 (en) * 2020-01-10 2022-04-06 Symphogen As ANTI-CD40 ANTIBODIES AND COMPOSITIONS
TW202144421A (en) * 2020-03-30 2021-12-01 大陸商正大天晴藥業集團股份有限公司 Antibodies binding cd40 and uses thereof
GB202008003D0 (en) * 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
US20210395366A1 (en) 2020-06-18 2021-12-23 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
TWI799959B (en) * 2020-08-21 2023-04-21 大陸商上海藥明生物技術有限公司 CD40 agonist antibodies and methods of use
KR20230048112A (en) * 2020-08-21 2023-04-10 우시 바이올로직스 (상하이) 컴퍼니 리미티드 CD40 Agonizing Antibodies and Methods of Using The Same
JP2023552812A (en) 2020-12-09 2023-12-19 ジャナックス セラピューティクス，インク． Compositions and methods related to tumor-activating antibodies targeting PSMA and effector cell antigens
WO2022136508A1 (en) * 2020-12-23 2022-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells
WO2022162177A1 (en) * 2021-01-29 2022-08-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Chlamydia trachomatis antigenic polypeptides and uses thereof for vaccine purposes
WO2023010094A2 (en) 2021-07-28 2023-02-02 Genentech, Inc. Methods and compositions for treating cancer
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
WO2023186111A1 (en) * 2022-04-02 2023-10-05 和铂医药(上海)有限责任公司 Antigen binding protein targeting cd40, and preparation therefor and use thereof
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023240058A2 (en) 2022-06-07 2023-12-14 Genentech, Inc. Prognostic and therapeutic methods for cancer
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
FI861417A0 (en) 1985-04-15 1986-04-01 Endotronics Inc HEPATITIS B YTANTIGEN FRAMSTAELLD MED REKOMBINANT-DNA-TEKNIK, VACCIN, DIAGNOSTISKT MEDEL OCH CELLINJER SAMT FOERFARANDEN FOER FRAMSTAELLNING DAERAV.
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (en) 1985-06-26 1992-08-01 Liposome Co Inc LIPOSOMAS COUPLING METHOD.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5182368A (en) 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
EP0304578B1 (en) 1987-06-22 2001-10-24 Medeva Holdings Bv Peptide comprising hepatitis B surface antigen
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
HU220204B (en) 1987-11-18 2001-11-28 Chiron Corp. Hcv polipeptides, hcv polinucleotides-containing such polinucleotides vectors and host cells-transformed with those diagnostics for detecting hcv infections, and immunoassay kit
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0449856B1 (en) 1988-12-16 2001-09-12 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Pneumolysin mutants and pneumococcal vaccines made therefrom
HU225068B1 (en) 1989-03-17 2006-05-29 Chiron Corp Process for producing diagnostics and vaccine of nanbh
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
SG48175A1 (en) 1989-07-25 1998-04-17 Smithkline Beecham Biolog Novel antigens and method for their preparation
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0546073T3 (en) 1990-08-29 1998-02-02 Genpharm Int Production and use of transgenic, non-human animals capable of forming heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
DK0590058T3 (en) 1991-06-14 2004-03-29 Genentech Inc Humanized heregulin antibody
CA2113113A1 (en) 1991-07-08 1993-01-21 Simon W. Kantor Thermotropic liquid crystal segmented block copolymer
DE4123760C2 (en) 1991-07-18 2000-01-20 Dade Behring Marburg Gmbh Seroreactive areas on the HPV 16 proteins E1 and E2
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5620886A (en) 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69433406T2 (en) 1993-10-01 2004-10-07 Immunex Corp ANTIBODIES AGAINST CD40
NZ278740A (en) 1993-12-23 1998-05-27 Immunex Corp Treating disease characterised by neoplastic cells expressing cd40 using a cd40 binding protein
ES2267100T5 (en) 1994-07-15 2011-04-08 The University Of Iowa Research Foundation IMMUNOMODULATING OLIGONUCLEOTIDES.
US5955087A (en) 1995-02-24 1999-09-21 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
AU699291B2 (en) 1995-03-01 1998-11-26 Immunex Corporation Method for stimulating an immune response
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur Proteinase k resistant surface protein of neisseria meningitidis
US5840306A (en) 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6069233A (en) 1996-10-03 2000-05-30 Memorial Sloan-Kettering Cancer Center Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
WO1998042752A1 (en) 1997-03-21 1998-10-01 Brigham And Women's Hospital Inc. Immunotherapeutic ctla-4 binding peptides
CA2297374A1 (en) 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
PL354714A1 (en) 1998-04-09 2004-02-09 Smithkline Beecham Biologicals S.A. Adjuvant compositions
EP2112166B1 (en) 1998-12-23 2018-11-21 Pfizer Inc. Human monoclonal antibodies to ctla-4
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
WO2001014556A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Novel b7-4 molecules and uses therefor
DE60033530T2 (en) 1999-08-24 2007-10-31 Medarex Inc. HUMAN ANTIBODIES TO CTLA-4 AND THEIR USES
WO2001039722A2 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
US6774226B1 (en) 1999-11-30 2004-08-10 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
CA2404164A1 (en) 2000-03-29 2001-10-04 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing immunogenicity of antigens
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US7063845B2 (en) * 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
JP2002088186A (en) 2000-09-14 2002-03-27 Showa Highpolymer Co Ltd Method for producing flame-retardant phenolic resin foam
US6794501B2 (en) 2001-05-04 2004-09-21 Ludwig Institute For Cancer Research Colon cancer antigen panel
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
EP1682178B8 (en) 2003-11-04 2010-09-01 Novartis Vaccines and Diagnostics, Inc. Methods of therapy for cancers expressing the cd40 antigen
CA2544368C (en) 2003-11-04 2014-04-01 Chiron Corporation Methods of therapy for b cell-related cancers
PT1682177E (en) 2003-11-04 2010-11-29 Xoma Technology Lt Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
PT1680141E (en) 2003-11-04 2010-12-20 Novartis Vaccines & Diagnostic Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
EP2243492A1 (en) 2003-11-04 2010-10-27 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
TWI380996B (en) 2004-09-17 2013-01-01 Hoffmann La Roche Anti-ox40l antibodies
GB2436472B (en) 2004-11-23 2009-11-25 Pip Co Ltd Built-in wall water service box
KR101017301B1 (en) * 2004-12-21 2011-02-28 메드임뮨 리미티드 Antibodies Directed to Angiopoietin-2 and Uses Thereof
SI2161336T1 (en) 2005-05-09 2013-11-29 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101562549B1 (en) 2005-05-10 2015-10-23 인사이트 홀딩스 코포레이션 Modulators of indoleamine 2,3-dioxygenase and methods of using the same
BRPI0613361A2 (en) 2005-07-01 2011-01-04 Medarex Inc isolated human monoclonal antibody, composition, immunoconjugate, bispecific molecule, isolated nucleic acid molecule, expression vector, host cell, transgenic mouse, method for modulating an immune response in an individual, method for inhibiting tumor cell growth in an individual, method for treating an infectious disease in a subject, a method for enhancing an immune response to an antigen in a subject, a method for treating or preventing an inflammatory disease in a subject, and a method for preparing the anti-pd-11 antibody
TWI382974B (en) 2005-12-20 2013-01-21 Incyte Corp N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
EP2589654A1 (en) * 2006-05-03 2013-05-08 The Regents of the University of Colorado, a body corporate CD40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
CL2007002650A1 (en) 2006-09-19 2008-02-08 Incyte Corp COMPOUNDS DERIVED FROM HETEROCICLO N-HIDROXIAMINO; PHARMACEUTICAL COMPOSITION, USEFUL TO TREAT CANCER, VIRAL INFECTIONS AND NEURODEGENERATIVE DISORDERS BETWEEN OTHERS.
US20080125470A1 (en) 2006-09-19 2008-05-29 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
PL2907827T3 (en) 2006-11-02 2019-03-29 Genentech, Inc. Humanized anti-factor D antibodies and uses thereof
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
CA2696761C (en) 2007-08-21 2017-02-14 Amgen Inc. Human c-fms antigen binding proteins
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
JP5583592B2 (en) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション IDO inhibitor
BRPI0821962A2 (en) 2008-01-03 2019-05-07 Univ De La Mediterrannee Aix Marseille Ii compositions and methods used during an anti-HIV treatment
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
MX343490B (en) 2008-07-16 2016-11-08 Inst For Res In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof.
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
CA2734330A1 (en) * 2008-09-19 2010-03-25 Medimmune, Llc Antibodies against sonic hedgehog homolog and uses thereof
KR20210060670A (en) 2008-12-09 2021-05-26 제넨테크, 인크. Anti-pd-l1 antibodies and their use to enhance t-cell function
US20120121591A1 (en) 2009-03-20 2012-05-17 Amgen Inc. SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3
MY162752A (en) 2009-03-20 2017-07-14 Amgen Inc Alpha-4-beta-7 heterodimer specific antagonist antibody
US20110007023A1 (en) 2009-07-09 2011-01-13 Sony Ericsson Mobile Communications Ab Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device
ES2601226T3 (en) 2009-10-28 2017-02-14 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
BR122021025338B1 (en) 2009-11-24 2023-03-14 Medimmune Limited ISOLATED ANTIBODY OR BINDING FRAGMENT THEREOF AGAINST B7-H1, PHARMACEUTICAL COMPOSITION AND ITS USES
PE20121398A1 (en) 2009-12-10 2012-10-26 Hoffmann La Roche BINDING ANTIBODIES PREFERENTIALLY TO THE EXTRACELLULAR DOMAIN 4 OF HUMAN CSF1R
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
CA2789071C (en) 2010-03-05 2018-03-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
CN102918060B (en) 2010-03-05 2016-04-06 霍夫曼-拉罗奇有限公司 Anti-human CSF-1R antibody and uses thereof
SI2566517T1 (en) 2010-05-04 2019-01-31 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CA2804550C (en) 2010-07-09 2021-01-05 Bionovion Holding B.V. Agonistic antibody to cd27
RU2551963C2 (en) 2010-09-09 2015-06-10 Пфайзер Инк. Molecules binding to 4-1bb
CA2824389A1 (en) 2011-01-10 2012-07-19 Emory University Antibodies directed against influenza
IT1403661B1 (en) * 2011-01-28 2013-10-31 Probiotical Spa EFFERVESCENT COMPOSITION IN THE SOLID FORM FOR USE IN VAGINAL APPLICATIONS FOR THE TREATMENT OF VAGINAL INFECTIONS.
MX2013010011A (en) * 2011-03-01 2014-10-24 Amgen Inc Sclerostin and dkk-1 bispecific binding agents.
NO2694640T3 (en) 2011-04-15 2018-03-17
KR101970025B1 (en) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Antibodies and other molecules that bind b7-h1 and pd-1
HUE051954T2 (en) 2011-11-28 2021-03-29 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
MX356337B (en) 2011-12-15 2018-05-23 Hoffmann La Roche Antibodies against human csf-1r and uses thereof.
JP6416630B2 (en) 2012-02-06 2018-10-31 ジェネンテック， インコーポレイテッド Compositions and methods for using CSF1R inhibitors
SG11201405087PA (en) 2012-03-02 2014-09-26 Regeneron Pharma Human antibodies to clostridium difficile toxins
AR090263A1 (en) 2012-03-08 2014-10-29 Hoffmann La Roche COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME
SG10201710574UA (en) 2012-03-15 2018-02-27 Janssen Biotech Inc Human anti-cd27 antibodies, methods and uses
JO3820B1 (en) 2012-05-03 2021-01-31 Regeneron Pharma Human antibodies to fel d1 and methods of use thereof
RU2670743C9 (en) 2012-05-11 2018-12-19 Файв Прайм Терапьютикс, Инк. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
JP6136343B2 (en) 2012-06-12 2017-05-31 株式会社リコー Information processing system, information processing method, program, and recording medium
UY34887A (en) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
US20140079699A1 (en) 2012-08-31 2014-03-20 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
ES2879552T3 (en) 2012-10-30 2021-11-22 Apexigen Inc Anti-CD40 antibodies and methods of use
JO3532B1 (en) 2013-03-13 2020-07-05 Regeneron Pharma Anti-il-33 antibodies and uses thereof
MX369574B (en) 2013-03-14 2019-11-13 Regeneron Pharma Human antibodies to grem 1.
MX2015010749A (en) 2013-03-14 2015-11-30 Regeneron Pharma Human antibodies to nav1.7.
AU2014296887A1 (en) 2013-08-02 2016-01-28 Aduro Biotech Holdings, Europe B.V. Combining CD27 agonists and immune checkpoint inhibition for immune stimulation
EP3041868A2 (en) 2013-09-05 2016-07-13 Aduro Biotech Holdings, Europe B.V. Cd70-binding peptides and method, process and use relating thereto
KR102264548B1 (en) 2014-11-21 2021-06-16 삼성전자주식회사 Semiconductor packages and fabrication method thereof
BR112018008891A8 (en) 2015-11-03 2019-02-26 Janssen Biotech Inc antibodies that specifically bind to pd-1 and tim-3 and their uses
WO2017184619A2 (en) 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof

Also Published As

Publication number Publication date
US20200369768A1 (en) 2020-11-26
WO2017184619A3 (en) 2017-12-21
EP3445783A2 (en) 2019-02-27
EA201892362A1 (en) 2019-04-30
JP2022088417A (en) 2022-06-14
AU2017252527A1 (en) 2018-11-08
US10865244B2 (en) 2020-12-15
CN109071665A (en) 2018-12-21
MA44723A (en) 2019-02-27
US20190322743A1 (en) 2019-10-24
KR20180133493A (en) 2018-12-14
MX2018012757A (en) 2019-06-24
SG11201808821WA (en) 2018-11-29
CN116059351A (en) 2023-05-05
US10633444B2 (en) 2020-04-28
BR112018071307A2 (en) 2019-02-26
JP2019521645A (en) 2019-08-08
IL262269B1 (en) 2023-04-01
US20200377606A1 (en) 2020-12-03
KR102414558B1 (en) 2022-06-29
CA3021328A1 (en) 2017-10-26
IL262269B2 (en) 2023-08-01
US10941201B2 (en) 2021-03-09
US20210147538A1 (en) 2021-05-20
WO2017184619A2 (en) 2017-10-26
US20180066053A1 (en) 2018-03-08
JP7038064B2 (en) 2022-03-17
CN109071665B (en) 2022-11-01
IL262269A (en) 2018-11-29

Similar Documents

Publication Publication Date Title
IL262269A (en) Agonistic antibodies that bind human cd40 and uses thereof
HK1245807A1 (en) Anti-mertk agonistic antibodies and uses thereof
HK1246308A1 (en) Antibodies against ox40 and uses thereof
IL258332A (en) Antibody agents specific for human cd19 and uses thereof
HK1248718A1 (en) Anti-cd40 antibodies and uses thereof
HK1249532A1 (en) Antigen binding complex having agonistic activity and methods of use
IL258268A (en) Agonistic antibodies specifically binding human cd40 and methods of use
SG10201912199XA (en) Anti-tim-3 antibodies and use thereof
EP3377102C0 (en) Anti-pd-1 antibodies and therapeutic uses thereof
IL263223A (en) Anti-cd40 antibodies and their uses
EP3541840C0 (en) Anti-hla-g antibodies and use thereof
HK1247091A1 (en) Therapeutic antibodies and uses thereof
IL269428A (en) Anti-c5a antibodies and uses thereof
IL274502A (en) Anti-ox40 antibodies and uses thereof
HK1245811A1 (en) Antibodies that bind human c6 and uses thereof